Attached files
| file | filename |
|---|---|
| EX-10.1 - DEVELOPMENT AND LICENSE AGREEMENT - Rezolute, Inc. | ex10_1.htm |
| EX-99.1 - PRESS RELEASE DATED AUGUST 7, 2017 - Rezolute, Inc. | ex99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 4, 2017
ANTRIABIO, INC.
(Name of registrant in its charter)
|
Delaware
|
000-54495
|
27-3440894
|
|
(State or jurisdiction
|
(Commission File
|
(IRS Employer
|
|
of incorporation or
|
Number)
|
Identification No.)
|
|
organization)
|
|
|
1450 Infinite Drive
Louisville, CO 80027
(Address of principal executive offices)
(303) 222-2128
(Registrant's telephone number)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 1.01 Entry into a Material Definitive Agreement
DEVELOPMENT AND LICENSE AGREEMENT
On August 4, 2017, AntriaBio, Inc. (the “Company” or “we” ) entered into a Development and License Agreement (“License Agreement “) with ActiveSite Pharmaceuticals, Inc. (“ActiveSite”) pursuant to which the Company acquired the rights to ActiveSite’s Plasma Kallikrein Inhibitor program (“PKI Program”). The Company desires to use the PKI Program to develop, file, manufacture, market and sell products for diabetic macular edema and other human therapeutic indications. The Company is required to make an upfront payment of $750,000 payable within five (5) days of the date the parties execute the License Agreement and then various milestone payments ranging from $1 million to $10 million when milestone events occur. The Company would also be required to pay royalty payments of 2% of sales for any products that use the PKI Program.
The foregoing description of the License Agreement is a summary of the material terms therein and is qualified in its entirety by the complete text of the License Agreement which is attached as Exhibit 10.1 hereto and incorporated herein by reference to this Item 1.01.
Item 7.01. Regulation FD Disclosure.
On August 7, 2017, we issued the press release attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in the press release is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended. The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01 Financial Statements and Exhibits
EXHIBIT DESCRIPTION
* The following exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ANTRIABIO, INC.
|
|
|
|
|
|
|
|
|
|
|
DATE: August 7, 2017
|
By:
|
/s/ Nevan Elam
|
|
|
|
Nevan Elam
Chief Executive Officer & Chairman of the Board
|
|
|
|
|
EXHIBIT INDEX
EXHIBIT DESCRIPTION
* The following exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.
4